Intranasal esketamine for patients with major depressive disorder: A systematic review and meta-analysis.
Journal of Psychiatric Research December 1, 2024 Soroush Oraee, Mohammadreza Alinejadfard, Hossein Golsorkh et al. 13 citations
A large number of people worldwide grapple with Major Depressive Disorder (MDD), and a significant portion of them confront resistance to conventional antidepressant treatments. Esketamine, an innovative intervention, has garnered attention due to its rapid-acting antidepressant effects. This meta-analysis aimed to evaluate the efficacy and safety of esketamine in individuals with MDD and...
DOI: 10.1016/j.jpsychires.2024.11.010 (opens in new tab)
Full text (opens in new tab)
Major depressive disorder
Treatment-resistant depression
Intranasal esketamine
Depression treatment
+3